Solutions
Asset optimization & commercialization
Situation
With an emerging gene therapy asset in the pipeline for a rare disorder, the client wanted to better understand why some gene therapies are more successful than others in the rare disease space
Approach
To investigate, we used secondary market research spanning viral vector research articles, clinical case studies, plus an examination of current supply chain and manufacturing challenges
Outcomes
We produced a robust report delineating the reasons for current successes and challenges of ex vivo and in vivo gene therapies, giving a range of future considerations and key cross-functional strategic recommendations
